Skip to main content
Fig. 7 | Genome Medicine

Fig. 7

From: Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Fig. 7

Receiver operating characteristic curves of predictive capacity of coverage-adjusted TMB from 7 different variant calling methods: consensus calling (see Methods), MuSE [51], MuTect [52], Pindel [53], RADIA [54], SomaticSniper [22], and VarScan 2 [23]. The upper panels depict the true positive rate (sensitivity, y-axis) and false positive rate (1-specificity, x-axis) for each method across all probability thresholds. The four panels represent models for four different cohorts based on different subsets of patients: All Cancers, which includes all patients, and Melanoma, RCC, and NSCLC, which include only melanoma, RCC, and NSCLC, respectively. The table in the lower panel reports the area under the curve (AUC) for each method (columns) applied to a different cancer cohort (rows), with colors above the methods indicating the color of the corresponding curve in the upper panels. TMB as determined by consensus calling (see “Methods”) is compared to the individual variant calling tools used in consensus calling. RCC = renal cell carcinoma, NSCLC = non-small cell lung cancer

Back to article page